<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733471</url>
  </required_header>
  <id_info>
    <org_study_id>LIDOGTC</org_study_id>
    <nct_id>NCT02733471</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Administering Lidocaine Spray in Oesophago-gastro-duodenoscopy</brief_title>
  <acronym>LIDOGTC</acronym>
  <official_title>Evaluation of the Efficacy and Safety of Administering Lidocaine Spray in Oesophago-gastro-duodenoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basque Health Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basque Health Service</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of the administration of lidocaine spray in
      oesophago-gastro-duodenoscopies. Half of the patients will receive lidocaine spray, while the
      other half will receive a placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of tolerance referred by the endoscopist in each group.</measure>
    <time_frame>Up to 15 minutes after endoscopy</time_frame>
    <description>Establish degree of tolerance referred by the endoscopist in each group according to the scale defined by Leich et al ( Gastrointestinal Endosc 1993;39:384-7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of tolerance referred by the patient in each group</measure>
    <time_frame>Up to 15 minutes after endoscopy</time_frame>
    <description>Establish degree of tolerance referred by the patient in each group according to the scale defined by Leich et al</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopist's level of satisfaction with the procedure in each group</measure>
    <time_frame>Up to 15 minutes after endoscopy</time_frame>
    <description>Endoscopist's level of satisfaction with the procedure according to a visual analogic scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's level of satisfaction with the procedure in each group.</measure>
    <time_frame>Up to 15 minutes after endoscopy</time_frame>
    <description>Patient's level of satisfaction with the procedure according to a visual analogic scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of completed procedures in control and lidocaine group</measure>
    <time_frame>Up to 15 minutes after endoscopy</time_frame>
    <description>Number of completed procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the total dose of propofol used in each group</measure>
    <time_frame>15 minutes before endoscopy</time_frame>
    <description>Dose of propofol used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish and compare the number of adverse events detected in control and lidocaine group</measure>
    <time_frame>Up to 15 minutes after endoscopy</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the number of patients with retrograde amnesia in each group</measure>
    <time_frame>Up to 15 minutes after endoscopy</time_frame>
    <description>Number of patients referring retrograde amnesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the number of patients with cough in each group</measure>
    <time_frame>Up to 15 minutes after endoscopy</time_frame>
    <description>Cough referred by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the number of patients with oropharyngeal discomfort in each group.</measure>
    <time_frame>Up to 15 minutes after endoscopy</time_frame>
    <description>Oropharyngeal discomfort referred by the patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">586</enrollment>
  <condition>Tolerance</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five lidocaine solution puffs (10mg lidocaine/puff) on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Five placebo solution puffs on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients aged over 18

          -  ASA I, II and III

          -  Non allergic to lidocaine or any of the drugs used in the study

          -  Consent form signed by the patient

        Exclusion Criteria:

          -  Stomach or esophagus diagnosed cancer

          -  Giant hiatal hernia diagnosed

          -  Zenker's diverticulum diagnosed

          -  Achalasia diagnosed

          -  Patients aged over 70

          -  Medical history of moderate to severe liver disease

          -  Medical history of moderate to severe renal insufficiency

          -  Medical history of moderate to severe Obstructive Sleep Apnea Syndrome (OSA) (AHI≥15).

          -  Severe respiratory insufficiency(asmtha or COPD) diagnosed

          -  Patients with encephalopaty active

          -  Patients with medical history of methemoglobinemia

          -  Patients with history of drug abuse

          -  Patients with mental impairment

          -  Patients with BMI≥ 35

          -  Use of pediatric tube
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Martin Marcos, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Basque Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Araba University Hospital</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Basque Health Service</investigator_affiliation>
    <investigator_full_name>Irene Martin Marcos</investigator_full_name>
    <investigator_title>Registered Nurse</investigator_title>
  </responsible_party>
  <keyword>Lidocaine</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Tolerance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

